Short Interest in Genfit S.A. (OTCMKTS:GNFTF) Declines By 85.9%

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 900 shares, a decrease of 85.9% from the February 28th total of 6,400 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Genfit Stock Performance

Shares of GNFTF remained flat at $3.54 on Wednesday. The stock has a 50 day moving average price of $3.54 and a two-hundred day moving average price of $4.47. Genfit has a 12 month low of $2.95 and a 12 month high of $5.55.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.